Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Day One Biopharmaceuticals, Inc. Day One Reports Third Quarter 2024 Financial Results and Corporate Progress October 30, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024 October 16, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports Second Quarter 2024 Financial Results and Corporate Progress July 30, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Oversubscribed $175.0 Million Private Placement July 30, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers June 18, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Sale of Priority Review Voucher for $108 Million May 30, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports First Quarter 2024 Financial Results and Corporate Progress May 06, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor April 23, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress February 26, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Two New Appointments to Board of Directors January 17, 2024 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference December 19, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine November 17, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference November 14, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports Third Quarter 2023 Financial Results and Corporate Progress November 06, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) October 30, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG) September 11, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience August 16, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports Second Quarter 2023 Financial Results and Corporate Progress August 07, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares June 12, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Pricing of Public Offering of Common Stock June 06, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Proposed Public Offering of Common Stock June 06, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma June 04, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference May 30, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 25, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting May 25, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports First Quarter 2023 Financial Results and Corporate Progress May 01, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting April 26, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress April 12, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress March 06, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Day One to Participate in the Cowen 43rd Annual Health Care Conference February 27, 2023 From Day One Biopharmaceuticals, Inc. Via GlobeNewswire Tickers DAWN Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
